INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipelin...

INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement:

The company continues striving to take responsibility for inappropriate actions of some former employees and has invested significant resources over the last several years to establish an effective compliance program and build an organizational culture of high ethical standards. Intending to learn from past events, we also continue working with relevant authorities to resolve issues related to inappropriate actions taken by former employees.

Last week’s federal indictments of five New York physicians involve allegations related to former employees. We understand that in addition to taking responsibility for former employees’ actions, the best ways to exhibit our desire to be a valued member of the healthcare community are to:

• focus on the actions of current employees and reinforce an organizational culture of high ethical standards;
• remain firmly committed to operating the business with a strong focus on the best interests of patients; and
• continue investing in innovating new treatment options for serious unmet patient needs.

We believe our actions over the last several years, including our significant investment in R&D programs, illustrate our commitment to these priorities and the company’s future.

About INSYSINSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need. 

CONTACT:			Corporate Communications	Investor Relations
			Joe McGrath	Jackie Marcus or Chris Hodges
			INSYS Therapeutics	Alpha IR Group
			480-500-3101	312-445-2870
			[e-mail]	[e-mail]